MedPath

Sprout Pharmaceuticals, Inc.

Sprout Pharmaceuticals, Inc. logo
🇺🇸United States
Ownership
Subsidiary
Established
2011-01-01
Employees
11
Market Cap
-
Website
http://addyi.com

Clinical Trials

13

Active:0
Completed:9

Trial Phases

2 Phases

Phase 1:1
Phase 3:12

Drug Approvals

1

FDA:1

Drug Approvals

ADDYI

Approval Date
Sep 1, 2021
FDA

Clinical Trials

Distribution across different clinical trial phases (13 trials with phase data)• Click on a phase to view related trials

Phase 3
12 (92.3%)
Phase 1
1 (7.7%)

Pharmacokinetics of Flibanserin in Postmenopausal Women With Hypoactive Sexual Desire Disorder (HSDD)

Phase 1
Completed
Conditions
Sexual Dysfunctions, Psychological
Interventions
First Posted Date
2010-08-25
Last Posted Date
2014-05-21
Lead Sponsor
Sprout Pharmaceuticals, Inc
Target Recruit Count
24
Registration Number
NCT01188603
Locations
🇺🇸

511.146.01003 Boehringer Ingelheim Investigational Site, Orlando, Florida, United States

🇺🇸

511.146.01005 Boehringer Ingelheim Investigational Site, Wichita, Kansas, United States

🇺🇸

511.146.01001 Boehringer Ingelheim Investigational Site, Kalamazoo, Michigan, United States

and more 1 locations

A 28-week Safety Study of Flibanserin in Pre- and Postmenopausal Women With Hypoactive Sexual Desire Disorder

Phase 3
Terminated
Conditions
Sexual Dysfunctions, Psychological
Interventions
First Posted Date
2010-04-14
Last Posted Date
2014-05-12
Lead Sponsor
Sprout Pharmaceuticals, Inc
Target Recruit Count
596
Registration Number
NCT01103362
Locations
🇺🇸

511.133.01074 Boehringer Ingelheim Investigational Site, Birmingham, Alabama, United States

🇺🇸

511.133.01141 Boehringer Ingelheim Investigational Site, Birmingham, Alabama, United States

🇺🇸

511.133.01046 Boehringer Ingelheim Investigational Site, Huntsville, Alabama, United States

and more 92 locations

Flibanserin for the Treatment of Hypoactive Sexual Desire Disorder in Postmenopausal Women in North America

Phase 3
Terminated
Conditions
Sexual Dysfunctions, Psychological
Interventions
Drug: Placebo
First Posted Date
2010-01-28
Last Posted Date
2014-06-17
Lead Sponsor
Sprout Pharmaceuticals, Inc
Target Recruit Count
748
Registration Number
NCT01057901
Locations
🇺🇸

511.156.01059 Boehringer Ingelheim Investigational Site, Birmingham, Alabama, United States

🇺🇸

511.156.01084 Boehringer Ingelheim Investigational Site, Tucson, Arizona, United States

🇺🇸

511.156.01053 Boehringer Ingelheim Investigational Site, Tuscon, Arizona, United States

and more 97 locations

12 Week Safety Trial of Flibanserin in Depressed Women Taking an SSRI or SNRI With Decreased Sexual Desire and Distress

Phase 3
Terminated
Conditions
Depression
Sexual Dysfunctions, Psychological
Interventions
First Posted Date
2009-12-29
Last Posted Date
2016-08-24
Lead Sponsor
Sprout Pharmaceuticals, Inc
Target Recruit Count
111
Registration Number
NCT01040208
Locations
🇺🇸

Clinical Innovations, Riverside, California, United States

🇺🇸

Mood & Anxiety Research, Fresno, California, United States

🇺🇸

Synergy Clinical Research Center, National City, California, United States

and more 36 locations

Fixed 100 mg Every Evening of Flibanserin vs Placebo in Premenopausal Women With Hypoactive Sexual Desire Disorder

Phase 3
Completed
Conditions
Sexual Dysfunctions, Psychological
Interventions
Drug: Placebo
First Posted Date
2009-10-16
Last Posted Date
2014-05-19
Lead Sponsor
Sprout Pharmaceuticals, Inc
Target Recruit Count
1090
Registration Number
NCT00996164
Locations
🇺🇸

511.147.01074 Boehringer Ingelheim Investigational Site, Birmingham, Alabama, United States

🇺🇸

511.147.01046 Boehringer Ingelheim Investigational Site, Huntsville, Alabama, United States

🇺🇸

511.147.01042 Boehringer Ingelheim Investigational Site, Mobile, Alabama, United States

and more 72 locations
  • Prev
  • 1
  • 2
  • 3
  • Next

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.